Clinical Trials - Fate Therapeutics

What is a clinical trial and why it matters

What is a clinical trial?

A clinical trial is a research study that explores how new treatments work and whether they are safe and could benefit patients. Fate Therapeutics is currently enrolling for clinical trials for CAR T-cell therapy treatment.

Advancing research.

By taking part in Fate’s CAR T-cell clinical trials, you may help researchers learn more about your condition and contribute to advances that could benefit future patients.

Access to innovative treatment.

Fate’s CAR T-cell therapy is being researched as a new potential option for patients whose current treatments are not working.

Fate Therapeutics is currently recruiting patients living with either certain autoimmune diseases or cancer types for CAR T-cell therapy trials.

For additional information or to inquire about participating in any of Fate’s clinical trials please contact: clinicaltrials@fatetherapeutics.com or download our patient brochure

Patient Journeys

Experience what participating in a CAR T-cell therapy clinical trial for Lupus may be like for you

Nebraska Medicine uses cutting-edge cell therapy to treat lupus for first time

A decade of suffering has given way to a new lease on life for an Omaha mother with lupus. Learn more here.

Omaha woman, who has suffered with lupus pain, finding relief after receiving novel therapy

Omaha mother of twins Lauren Koop Daughtrey underwent a newer type of CAR T-cell therapy to target her lupus this spring in a clinical trial at the University of Nebraska Medical Center. Learn more here.

Autoimmune Diseases

FT819-102 Study

This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate to severe active systemic lupus erythematosus (SLE), antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.

For additional information or to inquire about participating in the FT819-102 clinical trial please contact us.

Participation Expectations

Click Here

Study Locations (9)

United States

Fullerton, California, United States 92835
Providence Medical Foundation